Please login to the form below

Not currently logged in
Email:
Password:

Zynquista

This page shows the latest Zynquista news and features for those working in and with pharma, biotech and healthcare.

FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

It also turned down Lexicon Pharma and Sanofi’s SGLT2 inhibitor Zynquista (sotagliflozin) for this use in December, once again despite an earlier approval in Europe.

Latest news

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics